| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H24N2O2.C7H6O3 |
| Molecular Weight | 462.5375 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1O.COC2=CC3=C(C=CN=C3C=C2)[C@@H](O)[C@@H]4C[C@@H]5CCN4C[C@@H]5C=C
InChI
InChIKey=MAYUSTFJKJSJNC-DSXUQNDKSA-N
InChI=1S/C20H24N2O2.C7H6O3/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;8-6-4-2-1-3-5(6)7(9)10/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1-4,8H,(H,9,10)/t13-,14-,19-,20+;/m0./s1
Quinine soluble salts possess an extremely bitter taste, that may have a perplexing problem especially to children. That is why one of the most common combinations for oral administration is a slightly soluble quinine salicylate salt. It is known that now quinine is used in the absence of artemisin combination therapies (ARTs) to treat CQ resistant (CQR) P. falciparum malaria. Although the precise mechanism of the antimalarial activity of quinine is not completely understood, it can act via the inhibition on nucleic acid synthesis, on protein synthesis, and on glycolysis in Plasmodium falciparum, and also drug can affect via the binding with hemazoin in parasitized erythrocytes.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative |
Sample Use Guides
Prior to treatment, the in vitro susceptibility of isolates of P. falciparum to quinine was determined using the standardized procedure recommended by WHO. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that completely inhibited schizont formation. The MICs for quinine (mean, 3.02 uM) were significantly greater.
ACTIVE MOIETY
ACTIVE MOIETY
SUBSTANCE RECORD
